MONTREAL, Jan. 17, 2007 (PRIME NEWSWIRE) -- Viropro Inc. (OTCBB:VPRO) ("Viropro") is pleased to announce the appointment of Mr. Emilio S. Binavince, lawyer, as a new member of its Board of Directors. Mr Binavince brings Viropro a vast experience in legal affairs, international trade, business and tax planning, government litigation, and human rights, in various countries such as Canada and the United States, Asia, and Europe.
"We are very proud Mr. Binavince accepted to join our Board of Directors," said Dr. Jean-Marie Dupuy, President and CEO of Viropro. "His vast experience in various fields of activities at national and international levels will greatly benefit Viropro as it implements its business and growth strategy on international markets," added Dr. Dupuy.
"I am enthusiastic to join Viropro as Board Member. The company has a very interesting and low cost business model and my experience dealing at international levels should accelerate the signature of additional significant deals with partners in emerging countries," stated Mr. Binavince.
About Mr. Emilio S. Binavince
Mr. Binavince, counsel to the law offices of France Viele, was formerly a partner in Gowling, Strathy & Henderson. He was educated in the Philippines (LL.B.), United States (M.C.L., Tulane, LL.M., Harvard) and Germany (Doctoral Studies, Bonn). He is a member of the Bars of Ontario, Saskatchewan and the Philippines. He was the founding chairman, Joint MBA/LL.B. Program and co-Director of the Graduate Faculty of Law at the University of Ottawa. He is an advocate of over thirty years and has appeared as counsel in all levels of Court including the Supreme Court of Canada and various administrative tribunals.
Mr. Binavince is active as advisor, corporate director, and legal counsel on business and tax matters of foreign investors and ethnic communities in Canada and of Canadian investors in foreign countries, particularly in the Far East.
He is author of numerous articles and books in his area of practice and interest, and specializes in business and tax planning, and, government litigation.
About Viropro Inc.
Viropro Inc. conducts operations through its subsidiary Viropro International Inc., whose Head Office is located in Montreal, Canada. Viropro is a rapidly expanding biopharmaceutical company specializing in the transfer of its technologies for industrial production of biogeneric therapeutic proteins, excluding therapeutic vaccines, for the treatment of various diseases including cancer, diabetes, hepatitis or multiple sclerosis. The company's principal objective is to bring about the transfer of technology to pharmaceutical companies in emerging markets with unmet medical needs such as in South America, Asia and Africa. To expand its range of expertise in biopharmaceuticals excluding therapeutic vaccines, Viropro has concluded strategic alliances with various scientific and business partners renowned in national and international spheres. Viropro's business model rests on a strategy aimed at generating recurrent short and long-term revenues, all while maximizing the value of assets and profits of its shareholders.
For more information on Viropro Inc., please visit our website on www.viropro.com
Viropro Inc. Safe Harbor Statement
Except for any historic information contained herein, the matters discussed in this press release contain forward-looking statements that involve risks and uncertainties, which are subject to section 27A of the Securities Act of 1933 and section 21E of the Exchange Act of 1934, and are subject to safe harbor created by these sections. Any statements that express or involve discussions with respect to predictions, beliefs, plans, projections, objectives, goals, assumptions of future events or performances are not statements of historical fact and may be "forward-looking statements." Forward-looking statements in this release may be identified through the use of such words as "expects," "anticipates," "estimates," "believes," or statements indicating certain actions "may," "could," or "might" occur. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements, which involve numerous risks and uncertainties, including the Company's ability to market its products and services in a competitive environment as well as other factors.